Antibody mapping of the linear epitopes of CMY-2 and SHV-1 beta-lactamases.
Knowledge of the amino acids that define recognition of anti-beta-lactamase antibodies is critical to the interpretation of sensitivity and specificity of these antibodies when they are used in a clinical or research setting. To this end, we mapped the epitopes of the CMY-2 and SHV-1 beta-lactamases by using the SPOT synthesis method. Eight linear epitopes in SHV-1 and seven linear epitopes in CMY-2 were identified by using anti-SHV-1 and anti-CMY-2 polyclonal antibodies, respectively. The epitopes of SHV-1 were mapped to amino acids at the Ambler positions ABL 28 to 38, 42 to 54, 88 to 100, 102 to 114, 170 to 182, 186 to 194, 202 to 210, and 276 to 288. In the epitope spanning amino acids 102 to 114, alanine and X-Scan analysis demonstrated that D104, Y105, P107, and S109 are essential residues for antibody recognition. In the epitope containing amino acids 170 to 182, N170, L173, P174, G175, and D176 were immunodominant. In CMY-2 beta-lactamase, amino acids 4 to 16, 70 to 79, 211 to 223, 274 to 286, 289 to 298, 322 to 334, and 343 to 358 of the mature enzyme defined the major linear epitopes. A detailed analysis of the recognition sites that are located in an area analogous to the omega loop of class A beta-lactamases (V211 to V223) showed that the amino acids Q215 to E219 are important in antibody binding. Incubation of CMY-2 beta-lactamase with a 10-fold molar excess of anti-CMY-2 antibody for 60 min resulted in greater than 80% inhibition of nitrocefin hydrolysis. A 10-fold molar excess of anti-SHV-1 antibody reduced the activity of SHV-1 by 69%. Analysis of the CMY-2 and SHV-1 structures suggest that this reduction of hydrolytic activity may be due in part to the direct binding of antibodies to the omega loop, thereby hindering access of substrate to the active site.
Hujer
Andrea M
AM
Infectious Disease Section, Louis Stokes Veterans Affairs Medical Center, Cleveland, OH 44106, USA. Robert.Bonomo@med.va.gov
Bethel
Christopher R
CR
Bonomo
Robert A
RA
D000409:Alanine / Q000378:metabolism; D000595:Amino Acid Sequence; D000906:Antibodies / Q000737:chemistry / Q000302:isolation & purification; D019138:Antibodies, Blocking; D001665:Binding Sites; D001667:Binding, Competitive / Q000187:drug effects; D004797:Enzyme-Linked Immunosorbent Assay; D018604:Epitope Mapping; D004926:Escherichia coli / Q000201:enzymology; D008958:Models, Molecular; D008969:Molecular Sequence Data; D011487:Protein Conformation; D015203:Reproducibility of Results; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000276:immunology*
D000906:Antibodies; D019138:Antibodies, Blocking; D065093:beta-Lactamase Inhibitors; C103022:beta-lactamase CMY-2; C054882:beta-lactamase PIT-2; D001618:beta-Lactamases; D000409:Alanine